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Background/Aims: The usefulness of immunohistochemis-
try to screen for the microsatellite instability (MSI) phenotype 
in gastric cancer remains unclear. Moreover, the prognostic 
value of MSI phenotypes in gastric cancer has been debated. 
Methods: The clinicopathologic parameters and survival 
outcomes of 203 MSI-high (MSI-H) and 261 microsatellite-
stable (MSS) advanced gastric cancers (AGCs) were com-
pared. Next, we compared the immunohistochemistry results 
for hMLH1 and hMSH2 with those of a polymerase chain re-
action (PCR)-based method. Kaplan-Meier curves and a Cox 
proportional hazard regression model were used to conduct 
survival analyses. Results: The MSI-H AGCs were correlated 
with older age (p<0.001), female gender (p=0.018), distal 
location (p<0.001), larger size (p=0.016), and intestinal type 
(p<0.001). Multivariate analysis revealed that the MSI-H phe-
notype was an independent favorable factor that was related 
to overall survival in patients with AGC (p<0.001). Compared 
with the PCR-based analysis, immunohistochemistry exhib-
ited high sensitivity (91.1%) and specificity (98.5%) in the 
detection of MSI phenotypes. Conclusions: MSI-H gastric 
cancers have distinct clinicopathologic features and better 
prognoses, which suggests the necessity of MSI analysis in 
gastric cancer. Immunohistochemistry can be a useful and 
reliable screening method in the assessment of MSI status 
in gastric cancer. (Gut Liver 2015;9:629-635)
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INTRODUCTION
The clinicopathologic characteristics of microsatellite insta-
bility-high (MSI-H) colorectal carcinomas have been thoroughly 
investigated and well established: younger age, proximal loca-
tion, fewer lymph node metastases, and better overall survival.1,2 
Several similar studies on MSI-H gastric cancer (GC) have been 
reported, which showed distinct clinicopathologic features in-
cluding antral location, intestinal type by Lauren classification, 
frequent lymphoid stroma, lower prevalence of lymph node 
metastasis, and lower T stage, in contrast to microsatellite stable 
(MSS) GCs.3-8 Among the reports, a small number of studies 
could demonstrate favorable prognostic features of MSI-H GCs. 
However, a favorable effect of MSI-H phenotype was observed 
only in a specific subgroup in GC, which might be largely due 
to the limited number of study cases.4,5 If the MSI-H GCs were 
found to show unique clinicopathologic characteristics and 
perhaps even a better survival rate compared to MSS cases, it 
would be important for both pathologists and clinicians to ana-
lyze the MSI status of advanced gastric cancer in order to help 
detect patients with possible germline mutations and to estimate 
the clinical course.
Detection of MSI status in colorectal carcinoma is crucial and 
is now performed using polymerase chain reaction (PCR)-based 
method in many cases. Furthermore, efforts to replace the MSI 
test with immunohistochemistry (IHC) have been tried to over-
come the shortcomings of molecular techniques, and IHC analy-
sis with specific antibodies (hMLH1 and hMSH2) against MMR 
proteins has been validated as useful for investigating MSI sta-
tus in colorectal cancers.9-12 Although several studies attempt to 
evaluate the diagnostic utility of the IHC method as a screening 
tool of the MSI status,4,6 the feasibility of IHC method in gastric 
cancer remains unclear.
To clarify the prognostic benefit of MSI-H phenotype in ad-
vanced GC (AGC) and to verify the feasibility of IHC method in 
predicting the MSI status of GC, we compared the clinicopatho-
logic characteristics of a large series of MSI-H AGCs to those of 
MSS AGCs and evaluated the sensitivity and specificity of IHC 
to determine the MSI status.
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MATERIALS AND METHODS
1. Patients and samples
From January 2005 to December 2011, a total of 7,366 sur-
geries for GC patients (3,911 early GC and 3,371 AGCs) were 
carried out at Yonsei University Hospital. Among them, 2,959 
cases (40%) were tested for MSI phenotype by PCR-based as-
say on the basis of the patient’s consent. Of the tested GCs, 203 
cases were MSI-H type AGC. Cases that underwent neoadjuvant 
chemotherapy as well as recurrent cases were excluded. We 
additionally selected a similar number of MSS AGCs (n=261). 
To adjust the follow-up period of MSS cases with that of MSI-
H AGCs, in each year, we consecutively selected the MSS cases 
with the same proportion of MSI-H AGCs.
Clinicopathologic parameters, including age, sex, tumor loca-
tion, tumor size, gross type, histologic type, depth of invasion, 
lymph node metastasis, distant metastasis, lymphovascular in-
vasion, and pTNM stage, were obtained by reviewing the medi-
cal records and pathologic reports. Tumor size was calculated 
by measuring the largest diameter of the tumor. Gross type was 
categorized by Borrmann’s classification and histologic type 
was evaluated according to the 2010 World Health Organiza-
tion (WHO)13 and Lauren’s classifications.14 Due to similarity 
with intestinal type on survival analysis, cases with mixed type 
on Lauren’s classification were regarded as intestinal type (data 
not shown). Pathologic TNM stage was evaluated in accordance 
with the seventh 2010 American Joint Committee on Cancer/In-
ternational Union Against Cancer (AJCC/UICC) staging system.15 
The clinical outcomes of patients were observed from the date 
of operation to the date of death or to May 1, 2013. Informed 
consent for MSI analysis was obtained from all patients. Autho-
rization for the use of included tissues for research purposes was 
obtained from the Institutional Review Board of Yonsei Univer-
sity College of Medicine (approval number: 4-2013-0460).
2. Microsatellite analysis 
Genomic DNA from tumor and nonneoplastic areas was 
extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Ger-
many) and tested with five microsatellite markers, two mono-
nucleotide repeats (BAT25 and BAT26), and three dinucleotide 
repeats (D2S123, D5S346, and D17S250), as recommended by 
the National Cancer Institute. PCR was performed using a fluo-
rescence-labeled multiprimer, HotStarTaq polymerase (Qiagen), 
and the GeneAmp PCR system 2700 (Applied Biosystems, Foster 
City, CA, USA), for which the process was composed of initial 
denaturation (15 minutes at 95oC), followed by 30 cycles of 
denaturation (1 minute at 94oC), annealing (1 minute at 57oC), 
and extension (1 minute at 72oC). Amplification was performed 
with a final 5 minutes at 72oC and the amplified PCR products 
were analyzed using the automated ABI PRISM sequencer 
model 3100 genetic analyzer (Applied Biosystems). MSI was de-
termined by size variation and the presence of additional bands 
in the PCR products from tumor DNA. Tumors were designated 
as MSI-H when at least two out of the five markers showed in-
stability, and as MSS when none of them showed instability.16 
MSI-low cases, which showed instability in only one marker, 
were excluded from this study.
Fig. 1. Representative histology and immunohistochemistry results. A microsatellite instability-high (MSI-H) case (A) exhibiting the loss of the ex-
pression of hMLH1 (B) and the intact expression of hMSH2 (C). Stromal lymphocytes were used as an internal positive control. The intact expres-
sion of hMLH1 (E) and hMSH2 (F) was evident in a microsatellite stable case (D). 
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3. Tissue microarray construction
To select representative tumor areas, hematoxylin and eosin 
(H&E)-stained slides were reviewed by a pathologist before 
constructing the tissue arrays. Tissue cores of 3 mm in diameter 
were transplanted from individual donor blocks to tissue array 
blocks. Each tissue array block contained 29 cases and one nor-
mal gastric mucosa as a landmark and internal control, with a 
total of 464 cases in 16 array blocks. H&E and cytokeratin IHC 
were performed to confirm the presence of tumor.
4. Immunohistochemistry
Paraffin-embedded tissue blocks were cut into 4 μm sections. 
IHC was performed using a Ventana XT automated stainer (Ven-
tana Corp., Tucson, AZ, USA) with antibody to hMLH1 (ready-
to-use, clone M1; Roche, Indianapolis, IN, USA) and hMSH2 
(1:300, clone G219-1129; BD Pharmingen, San Jose, CA, USA). 
Sections were deparaffinized using EZ Prep solution (Ventana 
Corp.). CC1 standard (pH 8.4 buffer containing Tris/borate/
EDTA) was used for antigen retrieval and blocked with inhibitor 
D (3% H2O2) for 4 minutes at 37
oC. Slides were incubated with 
primary antibody for 40 minutes at 37oC followed by a uni-
versal secondary antibody for 20 minutes at 37oC. Slides were 
incubated in streptavidin-horseradish peroxidase (SA-HRP) D 
for 16 minutes at 37oC and then the substrate, 3,3´-diaminoben-
zidine tetrahydrochloride (DAB) H2O2, was added for 8 minutes 
followed by hematoxylin and bluing reagent counterstaining at 
37oC. A loss of MMR protein expression was designated when 
none of the neoplastic epithelial cells showed nuclear staining, 
while normal expression was defined as the presence of nuclear 
staining of tumor cells, irrespective of the proportion or inten-
sity (Fig. 1). Infiltrating lymphocytes, stromal cells and adjacent 
nonneoplastic epithelium served as internal positive controls. 
Two pathologists (Yoon Sung Bae and Hyunki Kim) assessed the 
IHC results without awareness of the MSI status of each case.
5. Statistical analysis
The sensitivity and specificity of IHC detection were cal-
culated using molecular MSI results as standards. Sensitivity 
and specificity were defined as loss of hMLH1 and/or hMSH2 
expression in MSI-H and their intact expression in MSS GCs, 
respectively. The chi-square test and t-test were performed to 
determine the possible correlation between MSI phenotype and 
clinicopathologic parameters. Survival curves were analyzed us-
ing the Kaplan-Meier method, followed by the log-rank test for 
estimating significant differences. Multivariate survival analysis 
was performed using the Cox proportional hazard regression 
model. All of the data were analyzed using IBM SPSS version 
20.0 (IBM Corp., Armonk, NY, USA), and the results were con-
sidered to be statistically significant when the p-values were less 
than 0.05. 
RESULTS
1. Clinicopathologic characteristics according to MSI phe-
notype
The patients were composed of 315 males and 149 females, 
Table 1. Clinicopathologic Characteristics according to the Microsat-
ellite-Stable and Microsatellite Instability-High Phenotype in Gastric 
Cancer
Variable Total
MSS GC
(n=261) 
MSI-H GC
(n=203) 
p-value
Age, yr <0.001
    ≤60 209 140 (67.0) 69 (33.0)
    >60 255 121 (47.5) 134 (52.5)
Gender 0.018
    Male 315 189 (60.0) 126 (40.0)
    Female 149 72 (48.3) 77 (51.7)
Tumor size, cm <0.001
    ≤6 258 158 (61.2) 100 (38.8)
    >6 206 103 (50.0) 103 (50.0)
Tumor location <0.001
    Upper and middle 169 126 (74.6) 43 (25.4)
    Lower 295 135 (45.8) 160 (54.2)
Borrmann’s type <0.001
    I and II 163 66 (40.5) 97 (59.5)
    III and IV 301 195 (64.8) 106 (35.2)
Histologic type 0.001
    Well and moderately 189 89 (47.1) 100 (52.9)
    Poorly 275 172 (62.5) 103 (37.5)
Lauren’s classification <0.001
    Intestinal 290 133 (45.9) 157 (54.1)
    Diffuse 174 128 (73.6) 46 (26.4)
Lymphovascular invasion 0.972
    Absent 203 114 (56.2) 89 (43.8)
    Present 261 147 (56.3) 114 (43.7)
Depth of invasion <0.001
    pT2 and pT3 272 129 (47.4) 143 (52.6)
    pT4 192 132 (68.8) 60 (31.3)
Lymph node metastasis 0.030
    Absent 149 73 (49.0) 76 (51.0)
    Present 315 188 (59.7) 127 (40.3)
Distant metastasis 0.028
    Absent 435 239 (54.9) 196 (45.1)
    Present 29 22 (75.9) 7 (24.1)
pTNM stage <0.001
    I and II 218 97 (44.5) 121 (55.5)
    III and IV 246 164 (66.7) 82 (33.3)
Data are presented as number (%).
MSS, microsatellite-stable; GC, gastric cancer; MSI-H, microsatellite 
instability-high.
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with a mean age of 61 years (range, 26 to 88 years). The mean 
tumor size was 5.9 cm (range, 0.7 to 25 cm). In accordance with 
WHO classification, 189 (40.7%) were cases of well to moder-
ately differentiated tubular adenocarcinoma, 227 (48.9%) were 
cases of poorly differentiated tubular adenocarcinoma and sig-
net ring cell carcinoma, and 48 (10.3%) were defined as other. 
The 48 other cases were composed of mucinous carcinoma, car-
cinoma with lymphoid stroma (medullary carcinoma), and ad-
enosquamous carcinoma. Those cases were regarded as poorly 
differentiated tumor by definition. Of the 464 cases, 272 (58.6%) 
and 192 (41.4%) were pT2/3 and pT4, respectively. Lymph node 
metastasis was observed in 315 cases (67.9%) and 29 cases (6.3%) 
had distant metastasis. Grouped by pTNM stage, 58 cases (12.5%) 
were stage IB, 160 (34.5%) were stage II, 217 (46.8%) were stage 
III, and 29 (6.3%) were stage IV. The mean follow-up period was 
51 months (range, 1 to 100 months).
The correlation between clinicopathologic parameters and 
MSI phenotype is summarized in Table 1. The mean age was 
58.4 years in the MSS group and 64.2 years in the MSI-H group. 
The mean tumor size was 5.7 cm in the former group and 6.2 
cm in the latter. GCs with MSI-H phenotype were associated 
with older age (p<0.001), female gender (p=0.018), distal tumor 
location (p<0.001), larger tumor size (p<0.001), Type I or II gross 
type according to Borrmann’s classification (p<0.001), and well 
to moderately differentiated (p=0.001) and intestinal histologic 
types (p<0.001) according to WHO and Lauren’s classification. 
MSI-H GCs were also characterized by a lower pT stage (p<0.001) 
and lower nodal metastasis (p=0.030). 
2. Survival analysis
The results of univariate and multivariate survival analyses 
are summarized in Table 2. Upon univariate analysis, MSS 
phenotype (p<0.001), larger tumor size (>6 cm, p<0.001), Bor-
rmann’s type III/IV (p<0.001), poorly differentiated histology 
(p=0.011), diffuse type by Lauren’s classification (p<0.001), 
deeper depth of invasion (pT4, p<0.001), presence of lymph 
node metastasis (p<0.001), presence of metastasis (p<0.001), and 
presence of lymphovascular invasion (p<0.001) were correlated 
with poor survival outcomes. The multivariate analyses using 
those significant variables showed that the MSS phenotype was 
Table 2. Univariate and Multivariate Survival Analysis
Factor
Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
MSI
    MSI-H vs MSS 2.785 1.767–4.391 <0.001 1.798 1.095–2.935 0.020
Age, yr
    ≤60 vs >60 0.928 0.634–1.358 0.700 - - -
Gender
    Male vs female 1.277 0.861–1.896 0.224 - - -
Tumor size, cm
    ≤6 vs >6 2.435 1.646–3.601 <0.001 1.823 1.202–2.764 0.005
Tumor location
    U/M vs L 0.913 0.616–1.352 0.650 - - -
Borrmann’s type
    I/II vs III/IV 3.109 1.871–5.167 <0.001 1.745 1.022–2.981 0.041
Histologic type
    Well/moderately vs poorly 1.711 1.130–2.591 0.011 0.664 0.349–1.264 0.213
Lauren’s classification
Intestinal vs diffuse 2.491 1.696–3.659 <0.001 1.696 0.935–3.076 0.082
Depth of invasion
    pT2/3 vs pT4 4.076 2.691–6.173 <0.001 2.107 1.329–3.341 0.002
Lymph node metastasis
    Absent vs present 7.155 3.478–14.718 <0.001 3.707 1.758–7.816 0.001
Distant metastasis
    Absent vs present 4.199 2.553–6.906 <0.001 2.462 1.471–4.121 0.001
Lymphovascular invasion
    Absent vs present 3.136 1.976–4.978 <0.001 1.999 1.241–3.219 0.004
HR, hazard ratio; CI, confidence interval; MSI-H, microsatellite instability-high; MSS, microsatellite stable; U/M, upper or middle; L, lower.
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an independent risk factor for worse survival outcomes (hazard 
ratio, 1.798; 95% confidence interval, 1.095 to 2.935; p=0.020). 
In terms of other parameters, tumor size (p=0.005), Borrmann’s 
type (p=0.041), lymphovascular invasion (p=0.004), depth of 
invasion (p=0.002), lymph node metastasis (p=0.001), and dis-
tant metastasis (p=0.001) were correlated with patient survival. 
The survival benefit in MSI-H GCs was also demonstrated by 
Kaplan-Meier survival curves (Fig. 2A). Even when grouped 
according to stage, these tumors showed a better prognosis, par-
ticularly stage II (p=0.003) (Fig. 2B). Stage III tumors, although 
not statistically significant, were found to have a tendency to-
wards better overall survival (p=0.116) (Fig. 2C). Statistical sig-
nificance was achieved when the intestinal type cases were se-
lectively included (p=0.010) (Fig. 2D). Furthermore, the survival 
benefit of MSI-H GCs was additionally analyzed by separating 
cases into an hMLH1 loss group and an hMSH2 loss group. Loss 
of hMLH1 expression was significantly associated with a better 
prognosis (p<0.001 on univariate analysis and p=0.03 on mul-
tivariate analysis), while loss of hMSH2 expression tended to 
show survival benefit without statistical power (Supplementary 
Table 1, Fig. 3).
3. Immunohistochemical results 
As outlined in Table 3, of the 203 MSI-H cases, 185 cases 
showed loss of expression of either hMLH1 or hMSH2; 179 for 
hMLH1, 15 for hMSH2, and nine for both of them, indicating 
a sensitivity of 91.1%. In 261 MSS cases, 257 cases normally 
reacted to both proteins, for a specificity of 98.5%. Of the total 
464 cases, 22 cases showed a discrepancy between IHC and PCR 
results, including four cases of MSS and 18 cases of MSI-H, de-
termined on the basis of PCR-based analysis.
Fig. 2. Kaplan-Meier analysis of the overall survival outcomes of advanced gastric cancer (AGC) patients according to polymerase chain reaction 
(PCR)-based microsatellite instability (MSI) analyses. (A) MSI-high (MSI-H) AGCs were associated with significantly better survival rates than the 
microsatellite stable (MSS) AGCs (p<0.001), which was also observed in stage II (p=0.003) (B). (C) In stage III, the MSI-H AGCs exhibited a trend 
toward good prognoses compared with the MSS AGCs, although there was no statistical significance (p=0.116). (D) The intestinal-type MSI-H 
AGCs exhibited better overall survival than did the intestinal-type MSS AGCs, including in stage III (p=0.010).
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DISCUSSION
The previous studies showed that GCs with the MSI-H phe-
notype have relatively distinct clinicopathologic characteristics, 
including older age, distal location, larger tumor size, intestinal 
type according to Lauren’s classification, gross type II according 
to Borrmann’s classification, a lower rate of lymph node metas-
tasis, and lower pTNM stage.3-7,17 Similar results were found in 
this study. However, the survival benefits of MSI-H phenotype 
remains a matter of debate, because the numbers of patients 
with MSI-H GCs were not high enough to evaluate.4,5 With a 
large scale series of 203 MSI-H AGCs, we could demonstrate the 
survival benefit of MSI-H GCs.
Using the Cox proportional hazard regression analysis and 
Kaplan-Meier survival curves, we demonstrated that MSI-H GCs 
had a better overall survival outcome than MSS GCs. As sum-
marized in Table 1, however, the pT and pN stages were differ-
ent with statistical significance in both groups, which required 
stratified analysis. Therefore, we reanalyzed after stratifying 
for pTNM stage. In stage II, MSI phenotype was still a crucial 
factor in predicting increased survival rates. Also in stage III, 
although not statistically significant, GCs with MSI-H had a 
tendency towards favorable outcomes. Interestingly, if the cases 
are confined to intestinal type according to Lauren’s classifica-
tion, MSI-H GCs showed a better survival rate than MSS GCs 
with statistical significance even in stage III. Similar results were 
reported in our previous study.5 In that study, MSI-H GCs had 
more favorable outcomes than MSS GCs of the intestinal type, 
but not the diffuse type. The results of stage IV were hard to in-
terpret because of the limited number of cases.5
MSI status could be a significant factor not only in colorec-
tal cancers but also in GCs, given that MSI-H phenotype is a 
specific entity in GCs and has survival benefits. Although PCR-
based molecular examination has been regarded as a standard 
diagnostic method in the identification of microsatellite insta-
bility in many tumors, including colorectal carcinoma,16 IHC is 
more simple, rapid, and universally available than the molecular 
testing. The usefulness of IHC in predicting MSI status has pre-
viously been validated extensively in colorectal cancers and was 
found to have high sensitivity and specificity.10-12,18
In terms of GCs, although there have been several attempts to 
verify the efficacy of IHC, the results were not satisfactory, espe-
cially in terms of sensitivity.3,4,6 In our study, the results of IHC 
staining for antibodies against hMLH1 and hMSH2 showed a 
Fig. 3. Kaplan-Meier survival curves according to hMLH1 and hMSH2 expressions. The loss of hMLH1 expression was significantly associated 
with a survival benefit (A), whereas the loss of hMSH2 expression was associated with a tendency toward a better prognosis that did not reach 
statistical significance (B).
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Table 3. Immunohistochemical Results for hMLH1 and hMSH2 in the Screening of Microsatellite Instability Status
Group
hMLH1 hMSH2 hMLH1-loss or 
hMSH2-loss
hMLH1-intact and 
hMSH2-intactIntact Loss Intact Loss
MSI-H (n=203) 24 (11.8) 179 (88.2) 188 (92.6) 15 (7.4) 185 (91.1*) 18 (8.9)
MSS (n=261) 257 (98.5) 4 (1.5) 203 (100.0)  0 4 (1.5) 257 (98.5*)
Data are presented as number (%).
MSI-H, microsatellite instability-high; MSS, microsatellite stable.
*The values of 91.1% and 98.5% were the sensitivity and specificity, respectively, of the immunohistochemistry for the screening of the MSI phe-
notype of gastric cancers.
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satisfactory reliability (91.1% sensitivity and 98.5% specificity). 
The discrepancy between the data from previous studies and 
ours might have resulted partly from the larger number of cases 
studied. Additionally, as we could control the environment dur-
ing IHC procedures with automated IHC stainer, we could obtain 
high-quality, more reproducible, and more standardized IHC 
results. A small subset of MSI-H cancers may show mutation of 
other MMR genes rather than MLH1 and MSH2, such as PMS2 
and MSH6, which could be a reason of slight low sensitivity in 
this study.19 Even though the status of PMS2 and MSH6 also 
could be detected using IHC, it would not yield a cost-effective 
result. 
In conclusion, MSI-H GCs have distinct clinicopathologic 
features and a better prognosis, which suggests the necessity of 
MSI analysis in GCs. From a routine diagnostic standpoint, IHC 
may be a useful and reliable screening method in predicting 
MSI status in GCs and will reduce the number of cases that need 
to be tested by PCR-based analysis.
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